CJC-1295 No DAC & Ipamorelin: Research Bloodwork to Track

In the published literature on growth-hormone-axis peptides, the analytes reported as endpoints cluster into a few predictable groups: the GH/IGF-1 axis itself (serum growth hormone, IGF-1, IGFBP-3), glucose-regulation markers, other pituitary hormones used to check selectivity, and thyroid and lipid panels as secondary covariates. That is what appears in studies of GHRH analogs and ghrelin-receptor agonists as a compound class. Real Peptides supplies CJC-1295 No DAC and Ipamorelin as research-use-only materials and does not provide dosing, preparation, or monitoring guidance of any kind.

For a wholesale buyer, the useful version of this question is not "which panel" — it is "what documentation has to exist behind the vial before any analyte number is interpretable." That part is squarely a sourcing decision, and it is where this article spends most of its time.

The analyte groups that show up in the literature

When researchers publish on growth-hormone secretagogues and GHRH analogs, a recognizable set of laboratory measures recurs. None of the following is a protocol, a recommendation, or a monitoring plan. It is a description of what the literature on this compound class tends to report.

Two methodological points from that same literature are worth knowing, because they are the ones your technically literate customers will raise. First, published work generally establishes baseline values before any intervention and keeps the same assay and the same laboratory throughout, since immunoassay and LC-MS methods for GH and IGF-1 are not freely interchangeable. Second, IGF-1 reference ranges in the literature are age- and sex-stratified, which is why raw values without a reference frame are hard to compare across studies. These are research-design considerations, not guidance about people.

Why compound documentation decides whether the numbers mean anything

Here is the operator-level point. Any analyte panel is a measurement of a system that received a specific substance. If the identity, purity, and peptide content of that substance are not documented for the exact lot used, then every number in the log carries an unquantified variable. A result that looks like a compound effect can just as easily be an impurity profile, a peptide-content shortfall, or a mislabeled vial.

That is why purity documentation is a data-integrity issue before it is a marketing point. A few specifics your buyers care about:

HPLC purity versus peptide content. These are different numbers. Purity describes what fraction of the peptide material is the target sequence. Peptide content describes how much of the total vial mass is peptide at all, with the remainder typically counterions, residual water, and salts. A certificate that reports one without the other leaves a gap.

Identity confirmation. Purity by HPLC tells you the material is homogeneous. It does not by itself confirm the sequence. Mass-spectrometry identity confirmation is what ties the peak to the intended molecule — relevant here because CJC-1295 No DAC and Ipamorelin are structurally unrelated compounds that are frequently discussed together, and a sequence error would not necessarily show up as a purity problem.

Batch specificity. A certificate that is not tied to a lot number is a document about some batch, not yours. Lot traceability is the entire mechanism by which a research record can be reconstructed later.

Related-substance peaks. Truncated sequences, deletion products, and oxidation products are the ordinary output of peptide synthesis. The question is not whether they exist but whether the analysis looks for them and reports them.

Where your customers' questions stop and your counsel's work begins

Businesses reselling or stocking research compounds get asked protocol questions constantly. The disciplined answer is that a supplier of research-use-only materials does not answer them, and neither should a reseller who wants to stay inside their lane. Real Peptides does not publish dosing, reconstitution, titration, or administration guidance for any catalog compound, and no volume or unit figures appear in its product education.

What can be discussed factually is the concentration framework: a vial has a stated peptide mass in milligrams, and any solution made from it has a concentration expressed in milligrams per milliliter. That relationship — mass divided by volume — is the ceiling of what belongs in supplier-side education. Anything past it is a preparation instruction.

On licensing and resale, treat every question as one for your attorney and your state board rather than for a supplier's blog. The questions worth bringing to counsel usually include: how research-use-only labeling must be presented in your jurisdiction and on your own materials; whether your entity type and any professional license you hold create additional obligations; what your obligations are if you resell rather than consume materials internally; what recordkeeping you are expected to maintain; and how your marketing language is likely to be read by a regulator. None of these has a single national answer, requirements differ by state and by business model, and the framework shifts over time. This section is informational and is not legal advice — get a written opinion from your own counsel before you build a catalog around any assumption.

What to verify before you commit to any supplier

The verification checklist is short, and most suppliers fail it in the same predictable places.

Are COAs public and free? Some programs treat certificates as a gated asset — available after purchase, on request, or as a paid add-on. That inverts the logic. A certificate exists so a buyer can evaluate material before committing, which means it should be viewable before the order.

Is the COA from a third-party laboratory, and can you see the lab's name? "Tested" with no named laboratory and no method detail is an assertion, not evidence.

Does the certificate match the lot you will receive? Ask how lot numbers on the vial map to published documents. If nobody can explain the mapping, there isn't one.

Is pricing published, or does every conversation start with a quote? Hidden pricing is usually a sign that price is set by what the buyer looks like they can pay. Published tiers are auditable; quote-only programs are not.

Are minimums and fulfillment stated up front? Order minimums, where fulfillment originates, and how reorders work should be answerable before you apply, not discovered afterward.

Does the supplier stay inside research-use-only framing in its own marketing? A supplier that drifts into human-use language in its copy is a compliance exposure attached to your brand. This is one of the most underrated items on the list.

How wholesale pricing tiers and minimums generally work

Mechanically, wholesale programs in this category price on volume and on category. Unit cost declines as commitment rises, minimums exist because filling, testing, and documenting a batch carries fixed cost regardless of order size, and different compound families carry different underlying synthesis economics — a short, well-characterized sequence and a complex one are not comparable inputs. Margins, markups, and realistic order sizes vary widely with volume, category, and the buyer's own business model, and any supplier quoting you a universal margin figure is guessing on your behalf. Model your own numbers against published tier pricing rather than someone else's projection.

What you should expect to see in writing: the tier thresholds, what each tier costs per unit, the minimum order to enter the program, and what happens to your pricing if volume drops in a slow quarter. Those four answers tell you more about a program than any sales call.

What Real Peptides does differently

Real Peptides operates its Wholesale Partner Program around documentation that a buyer can check independently.

99%+ HPLC purity. Purity is specified at 99% or higher across the catalog, including CJC-1295 No DAC and Ipamorelin.

Seven-panel batch testing. Every batch goes through a seven-panel analytical battery rather than a single purity check, with results tied to the batch.

Publicly verifiable COAs. Certificates are published and viewable — a buyer, or a buyer's customer, can check the lab results directly instead of taking a purity claim on faith. Certificates are not gated behind a purchase or sold separately.

US fulfillment in 5–7 days. Orders ship from US fulfillment with a stated 5–7 day window, so inventory planning runs on a known cycle.

A three-step wholesale application. Qualification is a three-step process rather than an open-ended sales cycle, and program pricing is published rather than quoted case by case.

Those are descriptive facts about how the program runs. What Real Peptides does not do is tell you what your research or your customers' research should look like, or supply any guidance about preparing or administering compounds. That boundary is deliberate.

The path for a qualified buyer

If you are a med spa, clinic, wellness center, telehealth company, or reseller building a catalog and you want purity documentation you can hand to a skeptical customer, the next step is the Wholesale Partner Program application. Review the published COAs for the compounds you plan to stock first — that is the fastest way to judge whether the documentation standard matches what your business needs before you commit to a tier.

Buyers evaluating this category typically begin with CJC-1295 No DAC 10mg and Ipamorelin 10mg, often alongside Tesamorelin 10mg as a related GHRH-analog research compound, and then work outward through the wider growth factor and tissue signaling research collection and the popular peptides catalog to build a shelf that matches their customer base.